Moderna, Inc. (NASDAQ:MRNA) Receives $60.63 Average PT from Brokerages

Moderna, Inc. (NASDAQ:MRNA) has been given an average rating of “Hold” by the twenty-three research firms that are presently covering the company, MarketBeat Ratings reports. Four investment analysts have rated the stock with a sell recommendation, fifteen have given a hold recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $60.63.

A number of research analysts recently weighed in on MRNA shares. Berenberg Bank lifted their price objective on shares of Moderna from $33.00 to $42.00 and gave the company a “hold” rating in a research note on Thursday, January 16th. Leerink Partners reduced their price objective on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating for the company in a research note on Thursday, January 16th. Bank of America reduced their price objective on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating for the company in a research note on Tuesday, February 11th. Argus downgraded shares of Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. Finally, Evercore ISI set a $50.00 price target on shares of Moderna in a report on Friday, February 14th.

Moderna Trading Up 0.3 %

Moderna stock opened at $30.37 on Wednesday. Moderna has a 1-year low of $29.25 and a 1-year high of $170.47. The firm has a market capitalization of $11.72 billion, a price-to-earnings ratio of -3.27 and a beta of 1.59. The firm has a 50 day simple moving average of $36.92 and a 200 day simple moving average of $49.88.

Institutional Trading of Moderna

A number of hedge funds have recently made changes to their positions in MRNA. Norges Bank bought a new stake in shares of Moderna during the 4th quarter worth $163,833,000. Voloridge Investment Management LLC lifted its holdings in shares of Moderna by 335.6% during the 4th quarter. Voloridge Investment Management LLC now owns 2,590,831 shares of the company’s stock worth $107,727,000 after acquiring an additional 1,996,003 shares during the last quarter. State Street Corp lifted its holdings in shares of Moderna by 12.1% during the 3rd quarter. State Street Corp now owns 16,847,212 shares of the company’s stock worth $1,125,899,000 after acquiring an additional 1,823,276 shares during the last quarter. FMR LLC lifted its holdings in shares of Moderna by 7.4% during the 4th quarter. FMR LLC now owns 18,664,634 shares of the company’s stock worth $776,075,000 after acquiring an additional 1,282,469 shares during the last quarter. Finally, Pictet Asset Management Holding SA lifted its stake in Moderna by 170.5% in the fourth quarter. Pictet Asset Management Holding SA now owns 1,766,398 shares of the company’s stock worth $73,447,000 after purchasing an additional 1,113,455 shares during the last quarter. 75.33% of the stock is owned by institutional investors.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.